[go: up one dir, main page]

WO2004050870A3 - Genetic switches for the detection of fusion proteins - Google Patents

Genetic switches for the detection of fusion proteins Download PDF

Info

Publication number
WO2004050870A3
WO2004050870A3 PCT/EP2003/013323 EP0313323W WO2004050870A3 WO 2004050870 A3 WO2004050870 A3 WO 2004050870A3 EP 0313323 W EP0313323 W EP 0313323W WO 2004050870 A3 WO2004050870 A3 WO 2004050870A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
detection
interacting
fusion proteins
interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/013323
Other languages
French (fr)
Other versions
WO2004050870A2 (en
Inventor
Stefan Bohlander
Nicole Froehlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Maximilians Universitaet Muenchen LMU
Original Assignee
Ludwig Maximilians Universitaet Muenchen LMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Maximilians Universitaet Muenchen LMU filed Critical Ludwig Maximilians Universitaet Muenchen LMU
Priority to AU2003289899A priority Critical patent/AU2003289899A1/en
Publication of WO2004050870A2 publication Critical patent/WO2004050870A2/en
Publication of WO2004050870A3 publication Critical patent/WO2004050870A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/72—Fusion polypeptide containing domain for protein-protein interaction containing SH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a complex comprising a fusion protein (a) comprising at least two epitopes; (b) protein A comprising an interaction domain capable of interacting with said first epitope of the protein of (a) and comprising a first effector domain; and (c) protein B comprising an interaction domain capable of interacting with said second epitope of the protein of (a) and comprising a second effector domain whereby said interaction domains of protein A and protein B are not capable of directly interacting with each other. Furthermore, specific nucleic acid molecules encoding said protein A and/or said protein B are provided as well as expressed protein A/B molecules. In addition, compositions, in particular pharmaceutical and diagnostic compositions are described which comprise the members of the complex of the present invention. Finally, the invention provides for in vivo and/or in vitro methods for the detection or elimination of a fusion protein, more preferably an oncogenic fusion protein.
PCT/EP2003/013323 2002-12-05 2003-11-26 Genetic switches for the detection of fusion proteins Ceased WO2004050870A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003289899A AU2003289899A1 (en) 2002-12-05 2003-11-26 Genetic switches for the detection of fusion proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02027501.2 2002-12-05
EP02027501 2002-12-05

Publications (2)

Publication Number Publication Date
WO2004050870A2 WO2004050870A2 (en) 2004-06-17
WO2004050870A3 true WO2004050870A3 (en) 2004-09-23

Family

ID=32405696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/013323 Ceased WO2004050870A2 (en) 2002-12-05 2003-11-26 Genetic switches for the detection of fusion proteins

Country Status (2)

Country Link
AU (1) AU2003289899A1 (en)
WO (1) WO2004050870A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107189986B (en) * 2017-07-25 2020-08-11 南京大学 A method for constructing reporter gene cell line based on endoplasmic reticulum stress and its application

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054360A1 (en) * 2005-05-12 2007-03-08 Zeren Gao Compositions and methods for modulating immune responses
ES2924071T3 (en) 2015-09-02 2022-10-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Specific antibodies to human T-cell immunoglobulin and ITIM domain (TIGIT)
CN107365783B (en) * 2017-07-26 2018-02-23 中国人民解放军南京军区南京总医院 A kind of new fusion of MiT families transposition clear-cell carcinoma and its detection primer and application
AU2020331401B2 (en) * 2019-08-12 2025-04-24 Celosia Therapeutics Pty Ltd Compositions and methods for treatment
WO2024026465A1 (en) * 2022-07-29 2024-02-01 The Broad Institute, Inc. Programmable pattern recognition compositions
CN117867032B (en) * 2024-01-22 2024-07-02 湛江中心人民医院 Construction method and application of aplastic anemia zebra fish model

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002054074A2 (en) * 2000-12-29 2002-07-11 Erasmus Universiteit Rotterdam Recognition of tumor-specific gene products in cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002054074A2 (en) * 2000-12-29 2002-07-11 Erasmus Universiteit Rotterdam Recognition of tumor-specific gene products in cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DA COSTA LUIS T ET AL: "Converting cancer genes into killer genes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 93, no. 9, 1996, 1996, pages 4192 - 4196, XP002275303, ISSN: 0027-8424 *
SHARIAT SHAHROKH F ET AL: "Adenovirus-mediated transfer of inducible caspases: A novel "death switch" gene therapeutic approach to prostate cancer", CANCER RESEARCH, vol. 61, no. 6, 15 March 2001 (2001-03-15), pages 2562 - 2571, XP002275304, ISSN: 0008-5472 *
TIRODE ET AL: "A conditionally expressed third partner stabilizes or prevents the formation of a transcriptional activator in a three-hybrid system", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 37, no. 272, 1997, pages 22995 - 22999, XP002051283, ISSN: 0021-9258 *
WANG DA-ZHI ET AL: "Potentiation of serum response factor activity by a family of myocardin-related transcription factors.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 99, no. 23, 12 November 2002 (2002-11-12), November 12, 2002, pages 14855 - 14860, XP002231778, ISSN: 0027-8424 (ISSN print) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107189986B (en) * 2017-07-25 2020-08-11 南京大学 A method for constructing reporter gene cell line based on endoplasmic reticulum stress and its application

Also Published As

Publication number Publication date
WO2004050870A2 (en) 2004-06-17
AU2003289899A1 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
CN101687915B8 (en) Cross-species specific CD3-ε binding domain
WO2002020569A3 (en) Mammalian genes; related reagents and methods
WO2005003296A3 (en) Albumin fusion proteins
WO2003070760A3 (en) Anti-amyloid beta antibodies and their use
WO2003059934A3 (en) Albumin fusion proteins
EP2277888A3 (en) Fusion proteins of albumin and erythropoietin
WO2007067730A3 (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
WO2004065540A3 (en) Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
WO2007133623A3 (en) Peptide diagnostic agent for lyme disease
WO2008008482A3 (en) Altered br3-binding polypeptides
WO2003030821A3 (en) Albumin fusion proteins
WO2008020335A8 (en) Immunogenic compositions for streptococcus agalactiae
WO2004024750A3 (en) Cd44-binding ligands
WO2002012899A3 (en) Peptides presented by cells
WO2001064877A3 (en) Human schizophrenia gene
WO2004050870A3 (en) Genetic switches for the detection of fusion proteins
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
WO2001064876A3 (en) Human schizophrenia gene
WO2006127822A3 (en) Scytovirin domain 1 related polypeptides
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof
WO2005065711A3 (en) Mammalian receptor proteins; related reagents and methods
WO2005023979A3 (en) Isolated s. mansoni nucleic acid molecules and uses thereof
WO2001030987A3 (en) Tankyrase h, compositions involved in the cell cycle and methods of use
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP